Herkel U, Pfeiffer N
Universitäts-Augenklinik, Johannes Gutenberg-Universität Mainz.
Ophthalmologe. 2001 Oct;98(10):929-33. doi: 10.1007/s003470170039.
Topical carbonic anhydrase inhibitors have been used since 1995 for medical glaucoma therapy, when dorzolamide was approved. In 2000, a second carbonic anhydrase inhibitor, brinzolamide, has become available in most of Europe. Both substances exhibit a comparable intraocular pressure-lowering activity, however, the side-effects are somewhat different. In the five years since its introduction, dorzolamide has had a positive risk-benefit-profile. In combination with any other topical agent, carbonic anhydrase inhibitors have an additive effect on the reduction of the intraocular pressure. Animal studies suggest that dorzolamide may improve ocular blood flow independent of the intraocular pressure; however, the significance for human glaucoma remains to be established.
自1995年多佐胺获批以来，局部用碳酸酐酶抑制剂已用于青光眼的医学治疗。2000年，第二种碳酸酐酶抑制剂布林佐胺在欧洲大部分地区上市。两种药物都具有相当的降低眼压活性，然而，副作用有所不同。自上市后的五年里，多佐胺的风险效益比良好。与任何其他局部用药联合使用时，碳酸酐酶抑制剂在降低眼压方面具有相加作用。动物研究表明，多佐胺可能独立于眼压改善眼部血流；然而，其对人类青光眼的意义仍有待确定。
